FDA Grants Fast Track Designation For Cubist's Late-Stage Antibiotic Candidate

Cubist Pharmaceuticals, Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product (QIDP) indications, Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).
Source: Pharmaceutical Online News - Category: Pharmaceuticals Source Type: news